Hemostemix Inc (TSE:HEM) has released an update.
Hemostemix Inc., a pioneer in autologous stem cell therapy, has engaged Oak Hill Asset Management to advise on capital market strategies, aiming to raise C$6 million to restart production of ACP-01 and fund a phase III clinical trial. The funds will enable leasing of production facilities in Puerto Rico and generate revenue by 2025 from compassionate treatments, leveraged by favorable tax incentives under Puerto Rico’s Act 60. The company highlights the safety and effectiveness of ACP in treating various heart diseases and peripheral arterial disease, with significant potential for no-option patient treatments.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.
